Lantern Pharma is trading at $0.78, down 6.01% at 10:45 a.m. ET on October 9; no clear company-specific catalyst for the decline has been identified. - The October 15 ThinkEquity presentation announcement and Taiwan trial-site approvals were positive updates, not reported explanations for the selloff. - Major U.S. indexes and biotech sector ETF XBI were higher while Lantern Pharma was lower, leaving the specific reason for the intraday decline unclear.